Mahsa Hojabri

Mahsa Hojabri

Auto-generated profile, based on publicly available information

Mahsa Hojabri

Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2025 in Acta Biomaterialia
Verified
Journal Article
Open access
MKMaryam Karimi
Maryam Karimi
AAArash Aslanabadi
Arash Aslanabadi
BABen Atkinson
Ben Atkinson
MHMahsa Hojabri
Mahsa Hojabri
AMArshi Munawwar
Arshi Munawwar
MSMohammad M. Sajadi
Mohammad M. Sajadi
Background Monoclonal antibodies (mAbs) effectively treat and prevent various diseases, but their clinical application is hindered by issues related to the route of administration and pharmacokinetics (PK). Intravenous (IV) administration is cumbersome, while subcutaneous (SC) administration is hampered by lower bioavailability and potential for immunogenicity. This study evaluated the efficacy of liposomal formulations in enhancing the subcutaneous (SC) delivery and PK of broadly neutralizing antibodies (bNAbs) directed against HIV. Methods mAbs were encapsulated in liposomes with and without PEGylation. The liposomes were characterized for particle size, polydispersity index, zeta potential, and release. Thereafter, mice were injected with free mAbs or liposome-encapsulated mAbs, and PK was evaluated. Results Liposomes exhibited sizes of 85-92 nm with negative surface charges. Encapsulation efficiencies were 61% for PEGylated and 58% for non-PEGylated liposomes. Stability testing over 16 weeks revealed that formulations remained stable at 4°C but showed leakage at 37°C. Cytotoxicity assays confirmed that the liposomal formulations did not affect cell viability or induce apoptosis in HMEC-1 cells. In vivo, PK studies in humanized FcRn mice indicated that the PEGylated formulations generally had higher half-life, Cmax, AUC, and MRT, and lower CL values compared to their non-PEGylated formulations of the same injection type. Both liposomal formulations showed improvements in bioavailability and extended half-life compared to free mAbs administered via SC and IV routes. Compared to the gold standard of IV free mAb injection, SC injection of antibodies encapsulated in PEGylated liposome had up to 80% higher bioavailability and 45% extension of half-life. Compared to the SC free mAb injection, the differences were even more pronounced, with liposomal SC injection having up to 113% higher bioavailability and 81% extension of half-life. Conclusion Overall, liposomal encapsulation effectively protected SC injected mAbs from degradation, facilitated sustained release, and improved PK profiles, suggesting a promising strategy for enhancing the therapeutic potential of mAbs in conditions that need repeated injections. Future work should further optimize liposomal formulations to increase loading capacity, stability, and release kinetics. STATEMENT OF SIGNIFICANCE: This study addresses a challenge in the administration of monoclonal antibodies (mAbs). Intravenous administration requires additional resources, including nursing staff, making it time-consuming and costly. Although subcutaneous (SC) administration offers a less expensive and more patient-friendly option, it suffers from lower bioavailability and potentially shorter half-life. In this study, we encapsulated mAbs in liposomal formulations specifically designed to enhance their pharmacokinetics by promoting efficient lymphatic transport. Compared with both SC and even IV administration of free antibodies, liposomal formulations of mAbs remarkably improve bioavailability and extend the half-life. This innovative approach combines the comfort of SC administration with enhanced pharmacokinetics, addressing the limitations of current SC delivery methods. Liposomal formulations have the ability to greatly improve SC mAb administration by reducing the amount of antibody needed to be administered, reducing the frequency of injections, and potentially protecting against immunogenicity.

30 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMasoomeh Raoufi
Masoomeh Raoufi
MHMahsa Hojabri
Mahsa Hojabri
DNDanial Samiei Nasr
Danial Samiei Nasr
HNHanieh Najafiarab
Hanieh Najafiarab
ASAryan Salahi-Niri
Aryan Salahi-Niri
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
This study aimed to assess the severity and outcomes of COVID-19 in pregnant women, focusing on laboratory and radiological discrepancies between pregnant women and matched nonpregnant women. In this retrospective cross-sectional analysis, we matched 107 nonpregnant women with 66 pregnant women in terms of age, comorbidities, and the interval between symptom onset and hospital admission. Demographic, clinical, laboratory, and radiological data were collected, and chest CT scans were evaluated using a severity scale ranging from 0 to 5. Logistic regression and adjusted Cox regression models were used to assess the impact of various factors on pregnancy status and mortality rates. Differences in several laboratory parameters, including the neutrophil-to-lymphocyte ratio, liver aminotransferases, alkaline phosphatase, urea, triglycerides, cholesterol, HbA1c, ferritin, coagulation profiles, and blood gases, were detected. Radiologic exams revealed that nonpregnant women had sharper opacities, whereas pregnant women presented with hazy opacities and signs of crypt-organizing pneumonia. A notable difference was also observed in the pulmonary artery diameter. The mortality rate among pregnant women was 4.62%, which was comparable to the 5.61% reported in nonpregnant patients. Compared with nonpregnant patients, pregnancy did not significantly affect the severity or mortality of COVID-19. Our study revealed discernible differences in specific laboratory and imaging markers between pregnant and nonpregnant COVID-19 patients.

10 March 2022 in Research Square
Verified
Preprint
Open access
PDF file
YFYeganeh Farsi
Yeganeh Farsi
MHMahsa Hojabri
Mahsa Hojabri
GEGolnaz Eslamian
Golnaz Eslamian
BSBibi Shahin Shamsian
Bibi Shahin Shamsian
RGRoxana Mansour Ghanaie
Roxana Mansour Ghanaie
SEShabnam Eskandarzadeh
Shabnam Eskandarzadeh
Cernunnos deficiency is a rare radiosensitive form of severe combined immunodeficiency (SCID). Herein, we report a patient with recurrent infections, birdlike face, microcephaly, Failure to thrive (FTT), and hypogammaglobinemia accompanied by considerable and rare features of sensorineural hearing loss and hypothyroidism with a mutation in splicing site of the third intron of non-homologous end joining 1 (NHEJ1) gene. The mutation was associated with T-B-NK + in flowcytometry. Distinct clinical manifestation along with a rarely reported genetic site mutation was noticeable in the reported case. The clinicians should be sensitive enough to suspect SCID in any patient with recurrent infections, microcephaly, FTT, and hypogammaglobinemia. Also, it is highlightable that every case of SCID with microcephaly should prompt us to the SCIDs with genetic mutations sensitive to radiation and further investigations are mandatory in highly suspicious patients.

1 September 2026 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
AAArash Aslanabadi
Arash Aslanabadi
MKMaryam Karimi
Maryam Karimi
LPLaura Powell
Laura Powell
LSLisa Mary Schumaker
Lisa Mary Schumaker
ASAshley Shutt
Ashley Shutt
MSMohammad M. Sajadi
Mohammad M. Sajadi
Background: Human papillomavirus (HPV)‐associated cancers are preventable with vaccination. Serologic assays monitor antibody responses, but their complexity and cost pose limitations when evaluating population level immunity. We developed an L1‐based assay for the detection of multiple type‐specific HPV antibodies. Methods: The Luminex‐based assay used recombinant L1 proteins from seven HPVs (HPV‐6/11/16/18/35/45/58) for the detection of type‐specific immunoglobulin (Ig)G and IgA. Cutoffs were established using plasma from infants and children. The assay was optimized and qualified using a sample set from a blinded proficiency panel developed at the Frederick National Laboratory for Cancer Research. Results: Sensitivity and specificity for anti‐HPV‐6/11/16/18/58 IgG were 100% at the Mean + 3 standard deviation [SD] and Mean + 5 SD thresholds. Sensitivity for HPV‐45 was 100% and 92.9% at the +3 SD and +5 SD thresholds, respectively. IgA detection showed moderate positivity among vaccinated individuals, with peak estimates of 96.4% (HPV‐11) and 85.7% (HPV‐58) at the +3 SD threshold. IgA was correlated with IgG (Spearman's ρ = 0.74). The L1‐assay differentiated high, intermediate, low, and negative response groups from the blinded samples for all HPV genotypes ( p < 0.0001). Conclusion: The L1‐binding assay has the potential to be a scalable option for high‐throughput detection of broad‐spectrum HPV immunoglobulins, but further standardization and validation are needed.

17 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMohammad M. Sajadi
Mohammad M. Sajadi
AAAbdolrahim Abbasi
Abdolrahim Abbasi
ZTZahra Rikhtegaran Tehrani
Zahra Rikhtegaran Tehrani
CSChristine Siska
Christine Siska
RCRutilio Clark
Rutilio Clark
ADAnthony DeVico
Anthony DeVico
Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with “first generation” bnAbs used alone or in combination show promising antiviral effects but also highlight that additional engineering of “enhanced” antibodies will be required for optimal clinical utility, while preserving or enhancing cGMP manufacturing capability. Here we report the engineering of an anti-CD4 binding-site (CD4bs) bnAb, N49P9.3, purified from the plasma of an HIV elite-neutralizer. Through a series of rational modifications we produced a variant that demonstrates: enhanced potency; superior antiviral activity in combination with other bnAbs; low polyreactivity; and longer circulating half-life. Additional engineering for manufacturing produced a final variant, eN49P9, with properties conducive to cGMP production. Overall, these efforts demonstrate the feasibility of developing enhanced anti-CD4bs bnAbs with greatly improved antiviral properties as well as potential translational value.